Drug intelligence / Profile preview

PF-04776548

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

PF-04776548 is a small molecule HIV integrase inhibitor developed by Pfizer. It was investigated as an antiretroviral agent for the treatment of HIV infections, with both intravenous and oral formulations studied. The compound reached phase I clinical trials, where its pharmacokinetics were evaluated in healthy subjects. Despite demonstrating high potency and an excellent resistance profile in preclinical studies, uncertainties regarding human pharmacokinetics limited further development[1][3][4].

Other names: CBR15S3HNJCBR-15S3HNJCBR 15S3HNJ1515856-61-7

Targets

Integrase allosteric pocket (HIV)

Beyond the preview

Go deeper on PF-04776548.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-04776548.

Explore the full profile